dapagliflozin
astrazeneca
['cardio']
the investigators of the deliver trial and others suggest that all patients with hf get sglt2 inhibitors, but sees differing effects depending on ejection fraction. #esccongress #cardiotwitter 
theheartorg | Medscape Cardiology is your best source for cardiovascular disease news online. https://t.co/Q8t8IR82zV